Glaucoma implants

Lorem ipsum dolor sit amet consectetur. Feugiat bibendum vitae mattis feugiat pellentesque suscipit vel. Molestie tellus facilisis sapien nisl eleifend eleifend adipiscing. Quis duis faucibus nulla tellus lacus nunc. Suspendisse consectetur quam tempor molestie nulla vulputate.

Sed ultricies feugiat morbi et vitae volutpat pharetra eget platea. Ipsum etiam turpis facilisi integer felis consectetur at scelerisque pretium. Sem quam tristique mi vehicula pulvinar dui.

Our solutions

TimoD

A non-biodegradable intra-ocular implant delivering timolol to treat glaucoma for
up to 9 years.

  • Discovery

  • Pre-Clinical

  • Clinical
    Phase I

  • Clinical
    Phase II

  • Clinical
    Phase III

  • Regular
    Approval

Clinical Phase I

TimoD

Unmet need

The major issue for the glaucoma treatment is the compliance to reduce intra-ocular pressure. Treat adult patients with primary open-angle glaucoma or ocular hypertension is the focus of our implants. It will strongly increase patient compliance and lower patient burden of daily medicating by removing undesirable side effects tied to the drug.

Technology

Our non-biodegradable intra-ocular implant sustained releasing precise dose of timolol in the eye. Designed for up to 9 years duration approval, our single intra-ocular implant is in shape of a flexible ring.

Delivery of drugs close to action site provides an impressive reduction of dose and side effects (no drug systemic passage) compared to eye drops.

Implantation

  • With a specific injector (preloaded).
  • Minimally invasive surgery mimicked on a cataract surgery (possible at the same time).
  • Duration: 15 minutes in a one-day clinic visit.

Timeline

  • Today
  • 2023
  • 2024
  • 2025
  • 2026
  • 2027
  • 2028
  • 2029
  • Today

    Clinical Phase 1

  • 2023

    Clinical Phase 2 & 3

  • 2029

    On market

BitamoD